Background and Aim: The magnitude of the risk of incident type 2 diabetes (T2D) and metabolic syndrome (MetS) among patients with nonalcoholic fatty liver disease (NAFLD) is poorly known. We gauged the risk of developing T2D and MetS in patients with NAFLD diagnosed by either serum liver enzymes (aminotransferases or gamma-glutamyltransferase [GGT]) or ultrasonography.Methods: Pertinent prospective studies were identified through extensive electronic data- base research, and studies fulfilling enrolment criteria were included in the meta-analysis. Results Overall, in a pooled population of 117020 patients (from 20 studies), who were followed-up for a median period of 5 years (range: 3–14.7 years), NAFLD was associated with an increased risk of incident T2D with a pooled relative risk of 1.97 (95% confidence interval [CI], 1.80–2.15) for alanine aminotransferase, 1.58 (95% CI, 1.43–1.74) for aspar- tate aminotransferase, 1.86 (95% CI, 1.71–2.03) for GGT (last vs first quartile or quintile), and 1.86 (95% CI, 1.76–1.95) for ultrasonography, respectively. Overall, in a pooled pop- ulation of 81411 patients (from eight studies) who were followed-up for a median period of 4.5 years (range: 3–11 years), NAFLD was associated with an increased risk of incident MetS with a pooled relative risk of 1.80 (95% CI, 1.72–1.89) for alanine aminotransferase (last vs first quartile or quintile), 1.98 (95% CI, 1.89–2.07) for GGT, and 3.22 (95% CI, 3.05–3.41) for ultrasonography, respectively.Conclusions: Nonalcoholic fatty liver disease, as diagnosed by either liver enzymes or ul- trasonography, significantly increases the risk of incident T2D and MetS over a median 5-year follow-up.
Nonalcoholic fatty liver disease is associated with an almost two-fold increased risk of incident type 2 diabetes and metabolic syndrome. Evidence from a systematic review and meta-analysis
TARGHER, Giovanni;
2016-01-01
Abstract
Background and Aim: The magnitude of the risk of incident type 2 diabetes (T2D) and metabolic syndrome (MetS) among patients with nonalcoholic fatty liver disease (NAFLD) is poorly known. We gauged the risk of developing T2D and MetS in patients with NAFLD diagnosed by either serum liver enzymes (aminotransferases or gamma-glutamyltransferase [GGT]) or ultrasonography.Methods: Pertinent prospective studies were identified through extensive electronic data- base research, and studies fulfilling enrolment criteria were included in the meta-analysis. Results Overall, in a pooled population of 117020 patients (from 20 studies), who were followed-up for a median period of 5 years (range: 3–14.7 years), NAFLD was associated with an increased risk of incident T2D with a pooled relative risk of 1.97 (95% confidence interval [CI], 1.80–2.15) for alanine aminotransferase, 1.58 (95% CI, 1.43–1.74) for aspar- tate aminotransferase, 1.86 (95% CI, 1.71–2.03) for GGT (last vs first quartile or quintile), and 1.86 (95% CI, 1.76–1.95) for ultrasonography, respectively. Overall, in a pooled pop- ulation of 81411 patients (from eight studies) who were followed-up for a median period of 4.5 years (range: 3–11 years), NAFLD was associated with an increased risk of incident MetS with a pooled relative risk of 1.80 (95% CI, 1.72–1.89) for alanine aminotransferase (last vs first quartile or quintile), 1.98 (95% CI, 1.89–2.07) for GGT, and 3.22 (95% CI, 3.05–3.41) for ultrasonography, respectively.Conclusions: Nonalcoholic fatty liver disease, as diagnosed by either liver enzymes or ul- trasonography, significantly increases the risk of incident T2D and MetS over a median 5-year follow-up.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
